Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.

Inclusion Criteria:

• Having the ability to voluntarily give their signed informed consent.
• Ophthalmologically and clinically healthy subjects.
• Being able to and willing to comply with scheduled visits, treatment plan, and otherstudy procedures.
• Age between 18 to 45 years.
• Male or female gender.
• Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of ahormonal contraceptive method or intrauterine device (IUD) during the study period.
• Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
• Corneal staining ≤ grade I on the Oxford Scale.
• Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.

Exclusion Criteria:

• History of hypersensitivity to fluoroquinolones, steroid anti-inflammatories, or anyof the components of the drugs under investigation.
• Use of ophthalmic medications from any pharmacological group.
• Use of medications by any other route of administration.
• Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, orantibiotics by any route of administration in the last 30 days.
• History of eye surgery in the last 6 months.
• Use of contact lenses for a period less than two weeks prior to the start of thestudy, and during the intervention period of this study.
• In the case of women: being pregnant, breastfeeding, or planning to become pregnantwithin the study period.
• Having participated in any clinical research study 30 days prior to inclusion in thisstudy.
• Having previously participated in this same study.
• History of any chronic-degenerative disease, including Diabetes Mellitus or SystemicArterial Hypertension.
• Diagnosis of glaucoma or ocular hypertension.
• Known diagnosis of liver or heart disease.
• Presenting active inflammatory or infectious disease at the time of entry into thestudy.
• Presenting unresolved lesions or traumas at the time of entry into the study.
• Having been subjected to non-ophthalmological surgical procedures in the last 3months.
• Being or having an immediate family member (e.g., spouse, parent/legal guardian,sibling, or child) who is an employee of the research site or the sponsor, and whodirectly participates in this study.
• Active smoking (specified as the consumption of cigarettes regardless of the amountand frequency, 4 weeks prior to study inclusion and during the intervention period ofthis study).
• Active alcoholism (specified as the consumption of alcoholic beverages, regardless ofthe amount and frequency, 72 hours prior to study inclusion and during theintervention period of this study). Elimination Criteria
• Withdrawal of their consent to participate in the study (informed consent form).
• Occurrence of a serious adverse event, whether related or not to the interventions,that in the opinion of the principal investigator (PI) and/or the sponsor, couldaffect the patient's fitness to safely continue with the study procedures.
• Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
• Non-tolerability or hypersensitivity to any of the drugs under investigation.
• Adherence < 80% determined by the subject's diary and corroborated by the final weightof the research products (RP) compared to the initial weight.